SCHEMBL12715

SCHEMBL12715

C[C@@H]1CCCNCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8225505 1.00
SCHEMBL1099645 1.00
SCHEMBL22580339 0.97 SMN1; SMN2 (0.42)
SCHEMBL21039971 0.97 SMN1; SMN2 (0.42)
SCHEMBL7976940 0.94
SCHEMBL7965486 0.92
SCHEMBL23938465 0.91 SMN1; SMN2 (0.39)
SCHEMBL21250630 0.89 ALDH1A1 (0.47)
SCHEMBL18849939 0.89 ALDH1A1 (0.47)
SCHEMBL24060812 0.89 ALDH1A1 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4269403-A1 AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF GT Apeiron Therapeutics Limited (HK) 2023-11-01 EP disclosed
US-11767312-B2 Phthalazinone compound, and preparation method therefor and medical use thereof GENENTECH, INC. (US) 2023-09-26 US disclosed
US-20230242510-A1 PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF SHANGHAI JEMINCARE PHARMACEUTICALS CO LTD (CN) 2023-08-03 US disclosed
WO-2023098656-A1 COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE BEIGENE, LTD. (GB) 2023-06-08 WO disclosed
WO-2023064880-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC. (US) 2023-04-20 WO disclosed
US-20220402883-A1 COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION ARRAKIS THERAPEUTICS, INC. 2022-12-22 US disclosed
WO-2022134642-A1 AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF 湃隆生物科技有限公司(香港) 2022-06-30 WO disclosed
US-10738076-B2 Lanosterol prodrug compound and preparation method therefor and use thereof ZHONGSHAN OPHTHALMIC CENTER, SUN YAT-SEN UNIVERSITY (CN) 2020-08-11 US disclosed
WO-2020132384-A1 THIENOPYRIDINE INHIBITORS OF RIPK2 CELGENE CORPORATION (US) 2020-06-25 WO disclosed
US-20190256548-A1 LANOSTEROL PRODRUG COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF ZHONGSHAN OPHTHALMIC CENTER, SUN YAT-SEN UNIVERSITY (CN) 2019-08-22 US disclosed
EP-2499146-B1 TRICYCLIC PYRAZOL AMINE DERIVATIVES MERCK SERONO SA (CH) 2016-09-21 EP disclosed
US-9073940-B2 Tricyclic pyrazol amine derivatives MERCK SERONO SA (CH) 2015-07-07 US disclosed
US-9073940-B2 Tricyclic pyrazol amine derivatives MERCK SERONO SA (CH) 2015-07-07 US disclosed
US-20120238545-A1 TRICYCLIC PYRAZOL AMINE DERIVATIVES MERCK SERONO SA (CH) 2012-09-20 US disclosed
US-20120238545-A1 TRICYCLIC PYRAZOL AMINE DERIVATIVES MERCK SERONO SA (CH) 2012-09-20 US disclosed
WO-2011058149-A1 TRICYCLIC PYRAZOL AMINE DERIVATIVES MERCK SERONO S.A. (CH) 2011-05-19 WO disclosed
EP-1740578-B1 4- 2- (CYCLOALKYLAMINO) PYRIMIDIN-4-YL ] - (PHENYL) - IMIDAZOLIN-2- ONE DERIVATIVES AS P38 MAP- KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES MITSUBISHI TANABE PHARMA CORP (JP) 2010-12-15 EP disclosed
US-20100009957-A1 NOVEL INHIBITORS OF BETA-LACTAMASE MERCK SHARP & DOHME CORP. 2010-01-14 US disclosed